| Editor’s note: The Fierce PM Tracker will not publish Monday, January 16 in observance of Martin Luther King Day. We’ll be back in your inboxes Tuesday, January 17. |
Today's Big NewsJan 13, 2023 |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now.
|
|
| By Angus Liu Roche’s pharma chief Bill Anderson is embarking on his next assignment outside the company. In search of his replacement, the Swiss pharma prefers an internal candidate, outgoing chairman Christoph Franz reportedly said. |
|
|
|
By Robert King New research from the American Cancer Society shows the cancer death rate has declined by 33% since 1991 thanks in part to major advances in treatment. |
By Conor Hale Illumina could well be facing the maximum fine the European Commission can impose, totaling up to 10% of its annual revenues, over the DNA sequencing giant’s premature acquisition of the blood testing company Grail, according to a report from Reuters. |
By Max Bayer TCR² Therapeutics appeared to become the latest biotech to make major staff reductions last week as it laid out its clinical and corporate vision for the new year. But Fierce Biotech can reveal that it was in fact the second round of layoffs at the company in less than six months, after TCR² quietly removed a fifth of its staff in August. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now.
|
|
By Zoey Becker After Moderna put a price range for the private market at between $110 and $130, White House press secretary Karine Jean-Pierre called the pricing “hard to justify” at a press briefing. |
By Paige Minemyer SAN FRANCISCO—As a week packed with meetings, presentations and more than a few rainstorms comes to a close, several key trends have emerged as ones to watch for health insurers heading into 2023. |
By Helen Floersh The Wellcome-funded project will see a new test developed that can detect multi-pathogen co-infections in a single swab. |
By Kevin Dunleavy Two years after discontinuing the use of rare blood cancer treatment Lumoxiti in Europe, AstraZeneca has done the same in the U.S. In a letter to healthcare providers, the company said it would pull the treatment from the market in July of this year and advised distributors to return packages of the drug starting in August. |
By Heather Landi Employee healthcare navigation company Transcarent is teaming up with The Clinic by Cleveland Clinic, the hospital's joint venture with telehealth company Amwell, to expand access to medical specialists. |
By Conor Hale Caris Life Sciences has tapped ConcertAI for a joint pitch to cancer researchers, clinicians and drug developers. |
By Max Bayer,Gabrielle Masson Novavax CEO Erck to retire after 12 years and overseeing COVID vaccine development. CureVac CEO steps aside after getting lapped in the COVID vaccine race. Nkarta promotes Shook to chief medical officer role. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we discuss the FDA's shifting stance on cancer drug approvals. Plus, we cover the annual JPM week and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
